Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Maldonado

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Cellular & Molecular Immunology|September 19, 2006
The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseasesJingsong Wang, Michael A Maldonado
Current Protocols in Immunology|April 25, 2008
Animal models for SLEPhilip L Cohen, Michael A Maldonado
Arthritis & Rheumatology (Hoboken, N.J.)|December 20, 2016
ReplyRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or AdalimumabRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosusArpita Choudhury, Michael A Maldonado, Philip L Cohen, et al.
Rheumatology and Therapy|October 24, 2019
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)Roy Fleischmann, Michael Weinblatt, Harris Ahmad, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 28, 2024
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled TrialRohit Aggarwal, Ingrid E Lundberg, Yeong-Wook Song, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 31, 2012
Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr miceTakashi Miwa, Lin Zhou, Michael A Maldonado, et al.
Arthritis Care & Research|October 17, 2015
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid ArthritisRoy Fleischmann, Michael E Weinblatt, Michael Schiff, et al.
The American Journal of Pathology|March 30, 2007
Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanismsTakashi Miwa, Michael A Maldonado, Lin Zhou, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cellular & Molecular Immunology|September 19, 2006
The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseasesJingsong Wang, Michael A Maldonado
Current Protocols in Immunology|April 25, 2008
Animal models for SLEPhilip L Cohen, Michael A Maldonado
Arthritis & Rheumatology (Hoboken, N.J.)|December 20, 2016
ReplyRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or AdalimumabRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosusArpita Choudhury, Michael A Maldonado, Philip L Cohen, et al.
Rheumatology and Therapy|October 24, 2019
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)Roy Fleischmann, Michael Weinblatt, Harris Ahmad, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 28, 2024
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled TrialRohit Aggarwal, Ingrid E Lundberg, Yeong-Wook Song, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 31, 2012
Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr miceTakashi Miwa, Lin Zhou, Michael A Maldonado, et al.
Arthritis Care & Research|October 17, 2015
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid ArthritisRoy Fleischmann, Michael E Weinblatt, Michael Schiff, et al.
The American Journal of Pathology|March 30, 2007
Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanismsTakashi Miwa, Michael A Maldonado, Lin Zhou, et al.
Pageof 3